When referring to the study of Rutherford et al. (2015) on short- and long-term effects of rTMS in Alzheimer's disease, we erroneously stated in our article (Lefaucheur et al., 2020) that a clinical benefit on cognitive performance (tested by the Montreal Cognitive Assessment) was observed at weeks 2–3, only in the real stimulation condition during an initial sham-controlled 4-week period of treatment, and that then this benefit was prolonged by “2 additional weeks” of open-label real rTMS. In fact, this extended open-label treatment was administered for up to 19 months in multiple 2-week blocks with 2–7 months intervals between blocks and was not limited to a single additional 2-week block of treatment immediately following the original 4 weeks of treatment. Therefore, the results of that open-label extended follow-up study support the value of long-term maintenance treatment using multiple rTMS sessions rather than be interpreted as short-term 2-week extension.
Corrigendum: “Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014–2018)” (Clinical Neurophysiology (2020) 131(2) (474–528), (S1388245719312799), (10.1016/j.clinph.2019.11.002)) / Lefaucheur, J. -P.; Aleman, A.; Baeken, C.; Benninger, D. H.; Brunelin, J.; Di Lazzaro, V.; Filipovic, S. R.; Grefkes, C.; Hasan, A.; Hummel, F. C.; Jaaskelainen, S. K.; Langguth, B.; Leocani, L.; Londero, A.; Nardone, R.; Nguyen, J. -P.; Nyffeler, T.; Oliveira-Maia, A. J.; Oliviero, A.; Padberg, F.; Palm, U.; Paulus, W.; Poulet, E.; Quartarone, A.; Rachid, F.; Rektorova, I.; Rossi, S.; Sahlsten, H.; Schecklmann, M.; Szekely, D.; Ziemann, U.. - In: CLINICAL NEUROPHYSIOLOGY. - ISSN 1388-2457. - 131:5(2020), pp. 1168-1169. [10.1016/j.clinph.2020.02.003]
Corrigendum: “Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014–2018)” (Clinical Neurophysiology (2020) 131(2) (474–528), (S1388245719312799), (10.1016/j.clinph.2019.11.002))
Leocani L.;
2020-01-01
Abstract
When referring to the study of Rutherford et al. (2015) on short- and long-term effects of rTMS in Alzheimer's disease, we erroneously stated in our article (Lefaucheur et al., 2020) that a clinical benefit on cognitive performance (tested by the Montreal Cognitive Assessment) was observed at weeks 2–3, only in the real stimulation condition during an initial sham-controlled 4-week period of treatment, and that then this benefit was prolonged by “2 additional weeks” of open-label real rTMS. In fact, this extended open-label treatment was administered for up to 19 months in multiple 2-week blocks with 2–7 months intervals between blocks and was not limited to a single additional 2-week block of treatment immediately following the original 4 weeks of treatment. Therefore, the results of that open-label extended follow-up study support the value of long-term maintenance treatment using multiple rTMS sessions rather than be interpreted as short-term 2-week extension.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
